Saana V.
- Country
- Finland
- Department
- Dept of Oncology and Radiotherapy
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 15 of 125 partner sites.
Specializations
Oncology Focus
This investigator specializes in treating multiple forms of advanced cancer, with particular emphasis on melanoma and prostate cancer management.
- Metastatic Melanoma Treatment
- Castration-Resistant Prostate Cancer
- Hepatocellular Carcinoma
The investigator's work encompasses both established and innovative therapeutic approaches for metastatic conditions.
Treatment Modalities
The investigator works with diverse therapeutic approaches including immunotherapy combinations and targeted therapies for cancer treatment.
- Novel Drug Administration Methods
- Combination Therapy Approaches
- Advanced Treatment Protocols
Their expertise extends to both subcutaneous and intravenous treatment administration methods.
Specialized Expertise
The investigator focuses on treating advanced stage cancers with particular attention to metastatic disease management.
- Unresectable Cancer Treatment
- Advanced Liver Cancer Therapy
- Novel Therapeutic Applications
Their work includes evaluation of innovative treatment approaches for previously treated patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.